Reduced mortality in cystic fibrosis patients treated with tobramycin inhalation solution

Division of Respiratory Diseases, Children's Hospital Boston, Harvard Medical School, Boston, Massachusetts 02115, USA. .
Pediatric Pulmonology (Impact Factor: 2.7). 01/2012; 47(1):44-52. DOI: 10.1002/ppul.21521
Source: PubMed


Though tobramycin inhalation solution has been used for over a decade to improve lung function and reduce exacerbations in patients with cystic fibrosis (CF), its effects on mortality have not been well-described. This study aimed to assess the association between use of tobramycin inhaled solution and mortality in patients with CF and chronic Pseudomonas aeruginosa (PA) infection.
Longitudinal logistic regression was used to assess the association between current-year reported use of tobramycin inhalation solution and subsequent-year mortality of patients meeting recommended criteria for tobramycin inhalation solution use in the United States Cystic Fibrosis Foundation's Patient Registry (1996-2008).
Among 12,740 patients meeting inclusion criteria, 2,538 deaths were observed during a median follow-up of 6 years. After regression adjustment, use of tobramycin inhaled solution was associated with a 21% reduction in the odds of subsequent year mortality (odds ratio (95% CI): 0.79 (0.72-0.88), P < 0.001). In our model, use of dornase alfa was also associated with a 15% reduction in the odds of subsequent year mortality (odds ratio (95% CI): 0.85 (0.76-0.95), P = 0.005). Underweight for age, CF-related diabetes, female gender, worse lung function and cultures positive for Pseudomonas aeruginosa or Burkholderia cepacia complex, among multiple other patient characteristics, were associated with significantly increased mortality. Adjusted mortality rates for patients reporting tobramycin inhalation solution use in all versus none of the follow-up years were 1.3% versus 2.1% at 2 years, 5.2% versus 8.0% at 5 years, and 9.9% versus 15.0% at 10 years.
After adjustment for multiple patient characteristics and known risk factors, use of tobramycin inhalation solution was associated with significantly reduced mortality among patients with CF.

Download full-text


Available from: Gregory S Sawicki, Jan 21, 2014
  • Source
    • "Recombinant human DNase (dornase alfa) has been developed to cleave high molecular weight DNA released by dead neutrophils that contributes to the tenacity of airway phlegm [92]. Daily inhalation of aerosolized dornase alfa can reverse early air trapping [93] and ventilation inhomogeneity [94]; decrease sputum markers of local inflammation [92,95]; reduce pulmonary exacerbation risk [33,35]; improve CF pulmonary function [33,35]; slow the rate of at which pulmonary function is lost [96]; and improve survival [97]. It is generally well-tolerated and has become a mainstay in the recommended treatments to maintain lung health [98]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Since the discovery of the gene associated with cystic fibrosis (CF), there has been tremendous progress in the care of patients with this disease. New therapies have entered the market and are part of the standard treatment of patients with CF, and have been associated with marked improvement in survival. Now there are even more promising therapies directed at different components of the pathophysiology of this disease. In this review, our current knowledge of the pathophysiology of lung disease in patients with CF is described, along with the current treatment of CF lung disease, and the therapies in development that offer great promise to our patients.
    Full-text · Article · Aug 2012 · BMC Medicine
  • Source
    • "Tobramycin inhalation solution (TIS) has been introduced for the long-term management of chronic P. aeruginosa infection, with a Cochrane review [20] suggesting some benefit from TIS in terms of lung function and pulmonary exacerbation rate but also concern regarding an increase in antibiotic resistance. A recent registry study examining data from the Cystic Fibrosis Foundation's Patient Registry has suggested that TIS use is associated with reduced mortality [21]. TIS has also been demonstrated to be effective in delaying re-infection in those with early P. aeruginosa infection [22]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Pseudomonas aeruginosa chronically infects patients with cystic fibrosis and is associated with greater morbidity. There has been limited progress on the clinical development of new antibiotics with novel modes of action. This review addresses some of the latest research developments on the exploitation of candidate adjuvant therapeutic agents that may act alongside conventional antibiotics as an alternative therapeutic strategy. After considering key mechanisms this opportunistic pathogen employs to control virulence, the progress of various strategies including the inhibition of quorum sensing, efflux pumps and lectins, and the use of iron chelators, bacteriophages, immunisation and immunotherapy is reviewed. Both therapeutic approaches in early development and clinical phase are discussed.
    Full-text · Article · Jun 2012 · European Respiratory Journal
  • Source
    • "Interestingly, a female disadvantage regarding a worse prognosis and impaired survival in the course of CF has been documented for years (Kerem et al., 1992; Dodge et al., 1993; FitzSimmons, 1993; Rosenfeld et al., 1997; Fogarty et al., 2000; O’Connor et al., 2003; Barr et al., 2011; Taylor-Robinson and Schechter, 2011). This so-called gender gap has been insufficiently explained by a series of risk factors in female patients, including a higher prevalence of CF-related diabetes (Adler et al., 2008), reduced activity levels (Selvadurai et al., 2004), a preponderance for early acquisition of P. aeruginosa and Bcc bacteria (Demko et al., 1995; Olesen et al., 2010; Sawicki et al., 2011), and estrogens (Coakley et al., 2008; Zeitlin, 2008; Tam et al., 2011). Most of these factors can be mitigated by the development of modern treatments and standardized intensive care (Verma et al., 2005; Viviani et al., 2011), but the importance of female sex hormones is currently being highlighted by several studies (Coakley et al., 2008; Zeitlin, 2008; Tam et al., 2011). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Long-term respiratory infections with Burkholderia cepacia complex (Bcc) bacteria in cystic fibrosis (CF) patients generally lead to a more rapid decline in lung function and, in some cases, to a fatal necrotizing pneumonia known as the "cepacia syndrome." Bcc bacteria are ubiquitous in the environment and are recognized as serious opportunistic pathogens that are virtually impossible to eradicate from the CF lung, posing a serious clinical threat. The epidemiological survey of Bcc bacteria involved in respiratory infections at the major Portuguese CF Treatment Center at Santa Maria Hospital, in Lisbon, has been carried out by our research group for the past 16 years, covering over 500 clinical isolates where B. cepacia and B. cenocepacia are the predominant species, with B. stabilis, B. contaminans, B. dolosa, and B. multivorans also represented. The systematic and longitudinal study of this CF population during such an extended period of time represents a unique case-study, comprehending 41 Bcc-infected patients (29 pediatric and 12 adult) of whom around 70% have been persistently colonized between 7 months and 9 years. During chronic infection, the CF airways represent an evolving ecosystem, with multiple phenotypic variants emerging from the clonal population and becoming established in the patients' airways as the result of genetic adaptation. Understanding the evolutionary mechanisms involved is crucial for an improved therapeutic outcome of chronic infections in CF. This review focuses on our contribution to the understanding of these adaptive mechanisms based on extensive phenotypic, genotypic, and genome-wide expression approaches of selected Bcc clonal variants obtained during long-term colonization of the CF airways.
    Full-text · Article · Dec 2011 · Frontiers in Cellular and Infection Microbiology
Show more